Agilent companion diagnostic expands ce-ivd mark in europe to include cervical cancer

Santa clara, calif.--(business wire)--agilent technologies inc. (nyse: a) today announced that its pd-l1 ihc 22c3 pharmdx, code sk006, is now eu ce-ivd–marked for use in cervical cancer. pd-l1 ihc 22c3 pharmdx can be used as an aid in identifying cervical cancer patients for whom treatment with keytruda® (pembrolizumab) may be appropriate.1 keytruda is an anti-pd-1 therapy developed by merck (known as msd outside the u.s. and canada). in europe, keytruda, in combination with chemotherapy with o
A Ratings Summary
A Quant Ranking